This page shows the latest Intra-Cellular Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Shares rocketed following the announcement. US biotech Intra-Cellular Therapeutics has scored approval for its antipsychotic drug Caplyta for the treatment of schizophrenia, to the delight of investors. . ... The approval is an early Christmas present
Says lumateperone could provide additional benefits over existing treatments. US biotech company Intra-Cellular Therapies says it could file its lead drug lumateperone for schizophrenia as early as next year after ... Intra-Cellular maintains this
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
More recently Sir Michael has served on the board of US-based biotech Intra-Cellular Therapeutics.
Sir Michael Rawlins joins board of Intra-Cellular Therapeutics. The former chair of England's cost-effectiveness body for medicines, Sir Michael Rawlins, has made a contentious move to the US ... His expertise in the cost-effectiveness of new
More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.
Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...